Quarter 2018 MD&A 1 Indorama Ventures Public Company Ltd Management Discussion and Analysis 1st Quarter 2018 Best Performance Since IPO Core EBITDA of $326 million – 49% increase year-on-year Core
รายงานการประชุมคณะกรรมการตรวจสอบ ครั้งที่ 4/2548 Ref.: SET-2017-026 December 22, 2017 Subject: Signing on the Memorandum of Understanding to Invest in Medical Service Business for Healthcare and
Understanding to Invest in Medical Service Business for Healthcare and Esthetics under Trademark “Wuttisak” dated December 22, 2017 Since Filter Vision Public Company Limited (“the Company” or “FVC”) declared to
downstream business in Integrated Oxides and Derivatives based out of advantaged Gulf Coast USA. Indorama Ventures 2nd Quarter 2019 MD&A 2 2Q 2019 Summary Financials Table 1: Core Financials of Consolidated
characteristics to other existing debt securities, except for their core objective of financing projects that contribute to environmental conservation and/or social development. These products therefore are not
to a 20% reduction in IVL’s core EBITDA. Operating cash flow through this period increased by 33% to $1.3B, as a result of lower prices and operational excellence. IVL has proposed a dividend of
growth driven by lifestyle fibers growth in India (IRSL). IVL reported US$281M of core EBITDA registering a more pronounced decline yoy as spreads came off from a strong 3Q18. IVL reported US$405M of OCF
Ventures 1st Quarter 2019 MD&A 1 Indorama Ventures Public Company Ltd Management Discussion and Analysis 1st Quarter 2019 Highlights Revenue $3.0 billion (THB 95.8 billion), +26% YoY Core EBITDA of $304
Indorama Ventures 1st Quarter 2019 MD&A 1 Indorama Ventures Public Company Ltd Management Discussion and Analysis 1st Quarter 2019 Highlights Revenue $3.0 billion (THB 95.8 billion), +26% YoY Core EBITDA
, Structural Improvements, Enhanced Portfolio, New Investment Strategy In 2018: Revenue $10.7 billion, +27% YoY Core EBITDA of $1.4 billion, +44% YoY, Core EBITDA margin 13% Net Profit (after Tax/NCI) of